2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

Coronavirus infections

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

2

Peptides

4

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156651
    Zevotrelvir

    EDP-235

    		 SARS-CoV Infection
    Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC50 ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections .
    Zevotrelvir
  • HY-172760
    CIM-834

    		Virus Protease SARS-CoV Infection
    CIM-834 is an orally active and selective inhibitor targeting the coronavirus membrane protein (M protein), which potently blocks viral assembly against SARS-CoV-2 and SARS-CoV. CIM-834 binds to the short form of the M protein (Mshort) in a non-covalent manner, stabilizing Mshort and preventing its conformational switch to the long form (Mlong) required for virion assembly, thereby inhibiting viral particle formation. CIM-834 is promising for research of COVID-19 and other coronavirus infections .
    CIM-834
  • HY-177303
    AXT-914

    		CaSR SARS-CoV Infection Metabolic Disease Endocrinology
    AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research .
    AXT-914
  • HY-176347S
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2

    		Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-W777433
    Cyclobenzaprine b-D-glucuronide

    		Endogenous Metabolite Infection Others
    Cyclobenzaprine b-D-glucuronide is a metabolite of Cyclobenzaprine. Cyclobenzaprine b-D-glucuronide can be used to treat diseases associated with coronavirus infection. Cyclobenzaprine b-D-glucuronide can be used to study the metabolic pathways of Cyclobenzaprine in the body and as a potential candidate for studying coronavirus treatment .
    Cyclobenzaprine b-D-glucuronide
  • HY-162604
    SARS-CoV-2-IN-90

    		SARS-CoV Infection
    SARS-CoV-2-IN-90 (compound 3i) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .
    SARS-CoV-2-IN-90
  • HY-P2296
    Abz-FRLKGGAPIKGV-EDDNP TFA

    		Fluorescent Dye Others
    Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .
    Abz-FRLKGGAPIKGV-EDDNP TFA
  • HY-176229
    Mpro/Cathepsin L-IN-2

    		SARS-CoV Cathepsin Virus Protease Infection
    Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (M pro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections .
    Mpro/Cathepsin L-IN-2
  • HY-P991551
    YS110

    		Dipeptidyl Peptidase p38 MAPK ERK Infection Cancer
    YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
    YS110
  • HY-172214
    AB-343

    		SARS-CoV Virus Protease Infection
    AB-343 is a selective covalent inhibitor of SARS-CoV-2 M pro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .
    AB-343
  • HY-175029
    ALG-097558

    		SARS-CoV Virus Protease Infection
    ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
    ALG-097558
  • HY-126085
    (±)-Alliin
    2 Publications Verification

    (±)-L-Alliin

    		 SARS-CoV Infection
    (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
    (±)-Alliin
  • HY-126085R
    (±)-Alliin (Standard)

    (±)-L-Alliin (Standard)

    		 Reference Standards SARS-CoV Infection
    (±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
    (±)-Alliin (Standard)
  • HY-P3492
    SARS-CoV-2-IN-34

    		SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
    SARS-CoV-2-IN-34
  • HY-173521
    JNJ-9676

    		SARS-CoV DNA/RNA Synthesis Infection
    JNJ-9676 is an orally active inhibitor of membrane (M) protein. JNJ-9676 has in vitro antiviral activity against SARS-CoV-2, SARS-CoV, and sarbecovirus from bats and pangolins. JNJ-9676 inhibits viral assembly by stabilizing the conformational changes of the M protein dimer, preventing the release of infectious viruses. JNJ-9676 has significant antiviral effects and can be used in research on the prevention and treatment of coronavirus infections .
    JNJ-9676
  • HY-156654
    Ibuzatrelvir

    PF-07817883

    		 SARS-CoV Virus Protease Infection
    Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
    Ibuzatrelvir
  • HY-174350
    CK2-IN-15

    		Casein Kinase SARS-CoV Infection
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .
    CK2-IN-15
  • HY-P990816
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)

    		SARS-CoV Infection
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .
    Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)
  • HY-173411
    DNJ-20

    		Glycosidase SARS-CoV Infection Inflammation/Immunology
    DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research .
    DNJ-20
  • HY-175344
    TMP1

    		SARS-CoV Virus Protease Ser/Thr Protease Infection Inflammation/Immunology
    TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM)/TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .
    TMP1
  • HY-174233
    PROTAC SARS-CoV-2 Degrader-1

    		PROTACs SARS-CoV Virus Protease Infection
    PROTAC SARS-CoV-2 Degrader-1 (Compound LLP019) is a SARS-CoV-2 M Pro PROTAC degrader with a DC50 value of 4.7 μM. PROTAC SARS-CoV-2 Degrader-1 induces M Pro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Degrader-1 is promising for research of COVID-19 and related coronavirus infections. (Pink: DH03 (HY-32717); Black: linker (HY-42149); Blue: Thalidomide-4-O-CH2-COO(t-Bu) (HY-42771) .
    PROTAC SARS-CoV-2 Degrader-1
  • HY-163029
    CTSL/B-IN-1

    		Cathepsin SARS-CoV Infection
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .
    CTSL/B-IN-1
  • HY-P990814
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)

    		SARS-CoV Infection
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)
  • HY-P990815
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)

    		SARS-CoV Infection
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .
    Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)
  • HY-109509
    Enoxaparin

    PK 10169; Enoxaparin sodium

    		 Factor Xa Thrombin SARS-CoV Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19 .
    Enoxaparin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: